AB is the current board chairman (opps, sorry. I meant chairperson) for PhRMA. How do you think that bodes for negotiations with the Trump Administration over Most Favored Nation Pricing? If AB negotiates this the same way we vastly overpay for acquisitions, all of pharma is screwed